• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Antihistamine Use and Ovarian Cancer Risk

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Previous literature suggests that histamines, which are known immune modulators, may be associated with cancer 
  • Histamine accumulation has been reported in ovarian tumors  
  • Verdoodt et al. (Maturitas, 2018) examined the association between antihistamine use and ovarian cancer risk

METHODS: 

  • Nationwide case-control study  
    • Women in Denmark aged 30-84 years  
    • Histologically verified first diagnosis of epithelial ovarian cancer 
  • Age-matched controls  
  • Prescription use, patient and demographic characteristics were obtained from nationwide registries 
  • The association between antihistamine use and ovarian cancer was evaluated in the context of  
    • Antihistamine use 
    • Menopausal status 
    • Histological subtype of ovarian cancer

RESULTS: 

  • 5,556 women with ovarian cancer | 83,340 age matched controls  
  • Ever use of antihistamines was not associated with overall ovarian cancer 
    • Odds Ratio (OR) = 0.97 (95% CI = 0.90–1.05) 
  • The lack of association remained in subanalyses for patterns of antihistamine use 
  • Antihistamine use was inversely association with ovarian cancer among pre-menopausal women (<50 year)  
    • OR = 0.72 (95% CI = 0.57-0.90) 
    • Inverse association was found only with mucinous ovarian cancer  
  • No association was seen in women ≥50 years 
    • OR = 1.02 (95%CI = 0.93–1.11)

CONCLUSION: 

  • Antihistamine use was not associated with increased risk for epithelial ovarian cancer 
  • Further research may elucidate whether there is a protective effect of antihistamines on mucinous ovarian carcinoma

Learn More – Primary Sources: 

Antihistamine use and risk of ovarian cancer: A population-based case-control study

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does NSAID Use Impact Risk for Ovarian Cancer?
Low Dose Aspirin and Breast Cancer Prevention – Results from the CTS Cohort
Do Contraceptives Decrease Risk for All Ovarian Cancers?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site